SecBot SecBot
PRESS-RELEASE ·Filed May 12, 2026

EVAX

Evaxion
NEUTRAL
Impact 4/10
Horizonmonths Processed6mo ago WireGlobeNewswire
Press release · Announcement
Actionable Insight • Neutral

Monitor the EHA 2026 poster presentation on June 13 for any data that could de-risk EVX-04 and attract partnership interest. The clinical trial application in H2 2026 is the next major catalyst.

DirectionNeutral
Confidencemedium
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$4.17
T+0 close · May 12, 2026 · via day close
Latest settled
−28.18%
T+60 · $3.00
Vs SPY
−32.56%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 12 $4.17entry
  2. T+1 · 6mo ago −0.24%α −0.82% · $4.16
  3. T+5 · 6mo ago −1.92%α −2.00% · $4.09
  4. T+20 · 5mo ago −9.11%α −7.39% · $3.79
  5. T+60 · 3mo ago −28.18%α −32.56% · $3.00
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Evaxion announced a poster presentation at the EHA 2026 Congress detailing preclinical data for EVX-04, an off-the-shelf therapeutic AML vaccine. The data supports progression toward clinical testing, with a clinical trial application planned for H2 2026. This is a positive pipeline update but remains early-stage and non-revenue generating.

Key Facts

  • EVX-04 is an off-the-shelf therapeutic AML vaccine targeting endogenous retrovirus (ERV) tumor antigens.
  • Preclinical data will be presented at EHA 2026 Congress on June 13, 2026.
  • Evaxion plans to submit a clinical trial application in the second half of 2026.
  • EVX-04 prevented tumor growth in preclinical tumor models.
  • AML is the most frequent leukemia, with a median age at diagnosis of 68 years and poor survival rates.

Financial Impact

No financial data disclosed; preclinical stage with no revenue impact.

Risk Factors

  • EVX-04 is still preclinical; clinical failure risk is high.
  • Evaxion has no approved products and requires additional capital to fund development.
  • Competition from other AML therapies could limit commercial potential.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
90% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3293006

Track record

50 reports on EVAX

Performance horizon

7 of 11 bullish or bearish reports moved the stock their way by T+1. Best: +22.94% at T+5 after the Mar 5, 2026 report. 10 of 11 went positive at some point.

Filters
  1. Nov 12, 20264d ago 6-K Neutral 2/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
  2. Nov 12, 20264d ago Press Release Neutral 1/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
  3. Nov 9, 20267d ago 6-K / F-1/A / PRESS-RELEASE Neutral 3/10 Entry $2.75 to $2.86 Now $2.77 +0.73% ▲ +4.00% +4.37% vs SPY
  4. Nov 6, 202610d ago 6-K Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
  5. Nov 6, 202610d ago Press Release Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
  6. Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
  7. Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
  8. Nov 3, 202613d ago 6-K Neutral 4/10 Entry $2.96 to $2.97 Now $2.77 −6.42% ▲ +0.34% −1.31% vs SPY
  9. Oct 30, 202617d ago 6-K Neutral 2/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
  10. Oct 30, 202617d ago Press Release Neutral 3/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
Showing 10 of 50

US Market Status

Market Closed · Opens in 6h 39m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 12, 2026